Yang SC - Search Results

1

Cost-effectiveness of lazertinib as first-line treatment in patients with EGFR-mutated advanced lung cancer.

Ku LE, Tsai JH, Chen LJ, Yang SC. Ku LE, et al. Among authors: yang sc. Ther Adv Med Oncol. 2025 Jan 3;17:17588359241312143. doi: 10.1177/17588359241312143. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 39759828 Free PMC article.

2

Cost Effectiveness of Exclusionary EGFR Testing for Taiwanese Patients Newly Diagnosed with Advanced Lung Adenocarcinoma.

Ou HT, Tsai JH, Chen YL, Wu TI, Chen LJ, Yang SC. Ou HT, et al. Among authors: yang sc. Pharmacoeconomics. 2025 Jan 3. doi: 10.1007/s40273-024-01462-z. Online ahead of print. Pharmacoeconomics. 2025. PMID: 39752129

3

Estimating time and transportation costs associated with lung cancer screening and diagnostic lung procedures in Taiwan: a cross-sectional survey in a medical centre.

Wu CH, Ku LE, Lin CY, Chung TJ, Liu HJ, Chao TH, Yang SC. Wu CH, et al. Among authors: yang sc. BMJ Open. 2023 Mar 10;13(3):e070647. doi: 10.1136/bmjopen-2022-070647. BMJ Open. 2023. PMID: 36898750 Free PMC article.

4

Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer.

Yang SC, Lin CC, Lai WW, Chang SM, Hwang JS, Su WC, Wang JD. Yang SC, et al. Ther Adv Med Oncol. 2018 Feb 5;10:1758834018755072. doi: 10.1177/1758834018755072. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 29434678 Free PMC article.

5

Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer.

Su PL, Wu YL, Chang WY, Ho CL, Tseng YL, Lai WW, Su WC, Lin CC, Yang SC. Su PL, et al. Among authors: yang sc. Ther Adv Med Oncol. 2018 Sep 25;10:1758835918797589. doi: 10.1177/1758835918797589. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 30263066 Free PMC article.

6

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer.

Yang SC, Kunst N, Gross CP, Wang JD, Su WC, Wang SY. Yang SC, et al. Front Oncol. 2021 Dec 9;11:760686. doi: 10.3389/fonc.2021.760686. eCollection 2021. Front Oncol. 2021. PMID: 34956882 Free PMC article.

7

Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naïve Metastatic Lung Adenocarcinoma.

Yang SC, Lin CC, Chen YL, Su WC. Yang SC, et al. Front Oncol. 2022 May 20;12:873111. doi: 10.3389/fonc.2022.873111. eCollection 2022. Front Oncol. 2022. PMID: 35669427 Free PMC article.

8

Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer.

Yang SC, Ou HT, Su WC, Wang SY. Yang SC, et al. Cancer Med. 2023 Apr;12(7):8838-8850. doi: 10.1002/cam4.5632. Epub 2023 Jan 18. Cancer Med. 2023. PMID: 36653947 Free PMC article.

9

Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan.

Yang SC, Lai WW, Hsu JC, Su WC, Wang JD. Yang SC, et al. PLoS One. 2020 Apr 8;15(4):e0231413. doi: 10.1371/journal.pone.0231413. eCollection 2020. PLoS One. 2020. PMID: 32267879 Free PMC article.

10

Estimating Costs Associated with Adverse Events in Patients with Advanced Lung Cancer.

Lin CY, Wu TI, Yang SC. Lin CY, et al. Among authors: yang sc. Clinicoecon Outcomes Res. 2024 Oct 19;16:761-769. doi: 10.2147/CEOR.S489783. eCollection 2024. Clinicoecon Outcomes Res. 2024. PMID: 39444786 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,434 results

Search Page

Filters